CARDIOVASCULAR RISK STRATIFICATION ACROSS DIFFERENT POPULATIONS: APPARENTLY HEALTHY INDIVIDUALS, PATIENTS WITH TYPE 2 DIABETES, AND ATHEROSCLEROTIC CARDIOVASCULAR DISEASE
Main Article Content
Abstract
Background: Atherosclerotic cardiovascular disease is a leading cause of mortality. Cardiovascular risk stratification plays a key role in prevention, but data in Vietnam remain limited.
Objectives: (1) To stratify 10-year cardiovascular risk in apparently healthy individuals and patients with type 2 diabetes; (2) To assess residual cardiovascular risk in patients with established atherosclerotic cardiovascular disease.
Methods: A multicenter, cross-sectional study with longitudinal follow-up was conducted in 481 patients aged ≥ 40 years. Cardiovascular risk was assessed using SCORE2/SCORE2-OP in apparently healthy individuals, SCORE2-Diabetes in patients with type 2 diabetes, and SMART score in patients with atherosclerotic cardiovascular disease.
Results: In apparently healthy individuals, very high, high, and low–moderate risk accounted for 38.0%, 32.3%, and 29.7%, respectively; SCORE2 significantly increased the proportion of high and very high risk compared to SCORE. In type 2 diabetes, most patients were classified as very high risk (64.8%). Among patients with atherosclerotic cardiovascular disease, residual risk was mainly moderate (43.3%) and low (29.1%), but 13.5% remained at extremely high risk.
Conclusions: Contemporary risk models improve cardiovascular risk stratification across different patient groups. SCORE2 tends to classify more patients into higher risk categories, while patients with diabetes and established cardiovascular disease exhibit substantial residual risk, highlighting the need for continuous risk assessment and individualized management.
Article Details
References
2. Visseren FL, Mach F, Smulders YM, et al. 2021 ESC Guidelines on cardiovascular disease prevention in clinical practice: Developed by the Task Force for cardiovascular disease prevention in clinical practice with representatives of the European Society of Cardiology and 12 medical societies With the special contribution of the European Association of Preventive Cardiology (EAPC). European heart journal. 2021;42(34):3227-3337.
3. Marx N, Federici M, Schütt K, et al. 2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes: Developed by the task force on the management of cardiovascular disease in patients with diabetes of the European Society of Cardiology (ESC). European Heart Journal. 2023;44(39):4043-4140. doi:10.1093/eurheartj/ehad192
4. Đoàn Phạm Phước Long, Nguyễn Thị Thúy Hằng, Nguyễn Thị Lan Nhi, et al. Nghiên cứu nguy cơ tim mạch bằng thang điểm SCORE2 và SCORE2-OP ở người trưởng thành mắc tiền tăng huyết áp tại tỉnh Thừa Thiên Huế. Tạp chí Tim mạch học Việt Nam. 05/31 2024;(109)doi:10.58354/jvc.109.2024.847
5. Trần Nguyễn Phương Hải, Nguyễn Nhật Tài, Nguyễn Minh Kha, et al. Reassessing Cardiovascular Risk Stratification in Vietnam: Insights from SCORE2 and the Original SCORE Model. Acta Inform Med. 2025;33(2):112-117. doi:10.5455/aim.2025.33.112-117
6. Truong HP, Tran HM, Huynh T, et al. Correlation between SCORE2-Diabetes and coronary artery calcium score in patients with type 2 diabetes mellitus: a cross-sectional study in Vietnam. Journal of Imaging. 2025;11(5):130
7. Kaasenbrood L, Boekholdt SM, Van Der Graaf Y, et al. Distribution of estimated 10-year risk of recurrent vascular events and residual risk in a secondary prevention population. Circulation. 2016;134(19):1419-1429.